Key Opinion Leaders (KOLs) are critical to the success of any research study. The experience and credibility of your KOLs add legitimacy to a clinical trial while also helping to mitigate any potential risks. As such, attracting KOLs to your study, and keeping them engaged for future research studies, is an important element in driving long-term success. Working with our clients, we’ve identified that a driving factor in attracting and retaining KOLs is to improve the quality of life for trial KOLs. The better the experience your KOL has working on your trial, the more likely you are to retain that KOL for future studies. This blog post breaks down three ways a clinical trial oversight system can help you attract and retain KOLs.
Understanding The Role of KOLs
As you already know, KOLs can be invaluable in meeting trial goals related to:
Patient enrollment and retention.
Clinical trial protocols/processes design.
Leveraging knowledge from prior studies and work in the field to implement best practices.
To properly support KOLs across all of these areas of responsibility, it’s critical that your clinical trial software provides the data and time-saving efficiencies that improve the quality of life for your KOLs.
3 Ways Your Clinical Trial Software Can Help You Support Your KOLs
Reduce the time it takes to schedule meetings.
Eliminate an overreliance on paperwork.
Let them communicate/engage on their preferred timelines.
Reduce the Time it Takes to Schedule Meetings
KOLs are in high demand, and their time is valuable. Your software should make it easy for KOLs to schedule meeting times that work for their busy lives. This includes allowing KOLs to see available time slots and providing automated reminders about upcoming meetings.
Your software should also make it easy for KOLs to prepare for meetings. It should provide access to relevant study materials and give KOLs the ability to take notes during meetings.
Clinical trial software, like Cloud Concinnity, allows oversight teams to quickly poll each other for availability and schedule meetings with ease. This eliminates cumbersome back-and-forth so that your KOLs can focus their time on the success of the study.
Eliminate an Overreliance on Paperwork
Don’t bog your KOLs down with copious amounts of paperwork. Relying on outdated methods of collecting and consolidating data can have an immediate negative impact on your KOLs’ quality of life.
Instead, take your note-taking to the cloud and empower your KOLs with the tools they need to effortlessly capture and share their notes with their team without the need to scan documents or mail physical copies.
Further, a tool like Cloud Concinnity allows your team to determine accessibility and security roles so that you can have confidence that only the permitted individuals are able to access the file.
Let them Communicate on Their Preferred Timelines
As we said before, KOLs are often busy people with hectic schedules. It’s important to let them communicate on their preferred timelines. Your clinical trial software can help you manage communication with KOLs by allowing you to send automatic updates and reminders. This will ensure that KOLs always have the most up-to-date information about your study and reduce the likelihood of missed deadlines.
Further, your platform should be device-agnostic, meaning that whether your KOL is in front of their desktop device or using their mobile phone, they should be able to drop in comments/notes quickly.
By making it easy for KOLs to work with you, your clinical trial software can help you attract and retain the experts you need to make your research successful.
If you’re looking for a cloud-based clinical trial oversight tool to help take your KOLs to the next level, look no further than Cloud Concinnity. Cloud Concinnity is a robust platform that empowers your trial oversight teams and data monitoring committees with a single, secure hub that centralizes all patient information, communications, processes, and reporting. If you have any questions or would like to see a free demo, please reach out to us today.